Comparison of zidovudine and tenofovir based regimens with regard to health-related quality of life and prevalence of symptoms in HIV patients in a Kenyan referral hospital

Jilian O. Etenyi, Faith A. Okalebo, Margaret Oluka, Kipruto A. Sinei, George O. Osanjo, Amanj Kurdi, Johanna C. Meyer, Brian Godman, Sylvia Opanga

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Zidovudine and tenofovir form the backbone of antiretroviral therapy in Kenya. However, their side-effects may affect the quality of life of patients. Objective: To compare the Health Related Quality of Life (HRQoL) of adult patients on tenofovir versus zidovudine based regimens in a referral hospital in Kenya to provide future guidance. Methods: A comparative cross-sectional study amongst adult out-patients on either tenofovir or zidovudine was undertaken in Kenyatta National Hospital
between 2015 and 2016. The Medical Outcome Study HIV Health Survey (MOS-HIV) was administered along with other key aspects of treatment. Linear regression analysis was performed to identify determinants of HRQoL. Results: Patients on zidovudine had a higher Physical Health Summary Score (PHSS) and Mental Health Summary Score (MHSS) compared to those on tenofovir. The presence of any symptom of the disease and a stated inability to cope were negatively associated with PHSS, while having a regular source of income improved PHSS. Being on tenofovir, symptom of illness (β=‐1.24; 95% CI [‐2.253, ‐0.226]), absence of pain (β=0.413; 95% CI [0.152, 0.674]) and patient stated inability to cope with HIV (β=‐1.029; 95% CI [‐1.441, ‐0.617]) affected the MHSS. Patients on tenofovir and second line regimens had more signs and symptoms of illness. Conclusion: Participants on zidovudine based regimens showed a better performance across all aspects of HRQoL. These are considerations for the future
LanguageEnglish
Article number984
Number of pages14
JournalFrontiers in Pharmacology
Volume9
Early online date12 Oct 2018
DOIs
Publication statusPublished - 12 Oct 2018

Fingerprint

Tenofovir
Zidovudine
Referral and Consultation
Quality of Life
HIV
Kenya
Mental Health
Health
Health Surveys
Signs and Symptoms
Linear Models
Outpatients
Cross-Sectional Studies
Regression Analysis
Outcome Assessment (Health Care)

Keywords

  • HRQOL
  • MOS-HIV
  • side effects
  • tenofovir
  • Zidovudine
  • anti-retroviral treatments
  • Kenya

Cite this

Etenyi, Jilian O. ; Okalebo, Faith A. ; Oluka, Margaret ; Sinei, Kipruto A. ; Osanjo, George O. ; Kurdi, Amanj ; Meyer, Johanna C. ; Godman, Brian ; Opanga, Sylvia. / Comparison of zidovudine and tenofovir based regimens with regard to health-related quality of life and prevalence of symptoms in HIV patients in a Kenyan referral hospital. In: Frontiers in Pharmacology . 2018 ; Vol. 9.
@article{47ed897ce3624963b94312dabe17b6cd,
title = "Comparison of zidovudine and tenofovir based regimens with regard to health-related quality of life and prevalence of symptoms in HIV patients in a Kenyan referral hospital",
abstract = "Introduction: Zidovudine and tenofovir form the backbone of antiretroviral therapy in Kenya. However, their side-effects may affect the quality of life of patients. Objective: To compare the Health Related Quality of Life (HRQoL) of adult patients on tenofovir versus zidovudine based regimens in a referral hospital in Kenya to provide future guidance. Methods: A comparative cross-sectional study amongst adult out-patients on either tenofovir or zidovudine was undertaken in Kenyatta National Hospitalbetween 2015 and 2016. The Medical Outcome Study HIV Health Survey (MOS-HIV) was administered along with other key aspects of treatment. Linear regression analysis was performed to identify determinants of HRQoL. Results: Patients on zidovudine had a higher Physical Health Summary Score (PHSS) and Mental Health Summary Score (MHSS) compared to those on tenofovir. The presence of any symptom of the disease and a stated inability to cope were negatively associated with PHSS, while having a regular source of income improved PHSS. Being on tenofovir, symptom of illness (β=‐1.24; 95{\%} CI [‐2.253, ‐0.226]), absence of pain (β=0.413; 95{\%} CI [0.152, 0.674]) and patient stated inability to cope with HIV (β=‐1.029; 95{\%} CI [‐1.441, ‐0.617]) affected the MHSS. Patients on tenofovir and second line regimens had more signs and symptoms of illness. Conclusion: Participants on zidovudine based regimens showed a better performance across all aspects of HRQoL. These are considerations for the future",
keywords = "HRQOL, MOS-HIV, side effects, tenofovir, Zidovudine, anti-retroviral treatments, Kenya",
author = "Etenyi, {Jilian O.} and Okalebo, {Faith A.} and Margaret Oluka and Sinei, {Kipruto A.} and Osanjo, {George O.} and Amanj Kurdi and Meyer, {Johanna C.} and Brian Godman and Sylvia Opanga",
year = "2018",
month = "10",
day = "12",
doi = "10.3389/fphar.2018.00984",
language = "English",
volume = "9",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",

}

Comparison of zidovudine and tenofovir based regimens with regard to health-related quality of life and prevalence of symptoms in HIV patients in a Kenyan referral hospital. / Etenyi, Jilian O.; Okalebo, Faith A.; Oluka, Margaret; Sinei, Kipruto A.; Osanjo, George O.; Kurdi, Amanj; Meyer, Johanna C.; Godman, Brian; Opanga, Sylvia.

In: Frontiers in Pharmacology , Vol. 9, 984, 12.10.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of zidovudine and tenofovir based regimens with regard to health-related quality of life and prevalence of symptoms in HIV patients in a Kenyan referral hospital

AU - Etenyi, Jilian O.

AU - Okalebo, Faith A.

AU - Oluka, Margaret

AU - Sinei, Kipruto A.

AU - Osanjo, George O.

AU - Kurdi, Amanj

AU - Meyer, Johanna C.

AU - Godman, Brian

AU - Opanga, Sylvia

PY - 2018/10/12

Y1 - 2018/10/12

N2 - Introduction: Zidovudine and tenofovir form the backbone of antiretroviral therapy in Kenya. However, their side-effects may affect the quality of life of patients. Objective: To compare the Health Related Quality of Life (HRQoL) of adult patients on tenofovir versus zidovudine based regimens in a referral hospital in Kenya to provide future guidance. Methods: A comparative cross-sectional study amongst adult out-patients on either tenofovir or zidovudine was undertaken in Kenyatta National Hospitalbetween 2015 and 2016. The Medical Outcome Study HIV Health Survey (MOS-HIV) was administered along with other key aspects of treatment. Linear regression analysis was performed to identify determinants of HRQoL. Results: Patients on zidovudine had a higher Physical Health Summary Score (PHSS) and Mental Health Summary Score (MHSS) compared to those on tenofovir. The presence of any symptom of the disease and a stated inability to cope were negatively associated with PHSS, while having a regular source of income improved PHSS. Being on tenofovir, symptom of illness (β=‐1.24; 95% CI [‐2.253, ‐0.226]), absence of pain (β=0.413; 95% CI [0.152, 0.674]) and patient stated inability to cope with HIV (β=‐1.029; 95% CI [‐1.441, ‐0.617]) affected the MHSS. Patients on tenofovir and second line regimens had more signs and symptoms of illness. Conclusion: Participants on zidovudine based regimens showed a better performance across all aspects of HRQoL. These are considerations for the future

AB - Introduction: Zidovudine and tenofovir form the backbone of antiretroviral therapy in Kenya. However, their side-effects may affect the quality of life of patients. Objective: To compare the Health Related Quality of Life (HRQoL) of adult patients on tenofovir versus zidovudine based regimens in a referral hospital in Kenya to provide future guidance. Methods: A comparative cross-sectional study amongst adult out-patients on either tenofovir or zidovudine was undertaken in Kenyatta National Hospitalbetween 2015 and 2016. The Medical Outcome Study HIV Health Survey (MOS-HIV) was administered along with other key aspects of treatment. Linear regression analysis was performed to identify determinants of HRQoL. Results: Patients on zidovudine had a higher Physical Health Summary Score (PHSS) and Mental Health Summary Score (MHSS) compared to those on tenofovir. The presence of any symptom of the disease and a stated inability to cope were negatively associated with PHSS, while having a regular source of income improved PHSS. Being on tenofovir, symptom of illness (β=‐1.24; 95% CI [‐2.253, ‐0.226]), absence of pain (β=0.413; 95% CI [0.152, 0.674]) and patient stated inability to cope with HIV (β=‐1.029; 95% CI [‐1.441, ‐0.617]) affected the MHSS. Patients on tenofovir and second line regimens had more signs and symptoms of illness. Conclusion: Participants on zidovudine based regimens showed a better performance across all aspects of HRQoL. These are considerations for the future

KW - HRQOL

KW - MOS-HIV

KW - side effects

KW - tenofovir

KW - Zidovudine

KW - anti-retroviral treatments

KW - Kenya

UR - https://www.frontiersin.org/journals/pharmacology

U2 - 10.3389/fphar.2018.00984

DO - 10.3389/fphar.2018.00984

M3 - Article

VL - 9

JO - Frontiers in Pharmacology

T2 - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - 984

ER -